| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | $86.2M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Omeros Corporation is a clinical-stage biopharmaceutical company discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases and orphan indications. Its lead candidate Narsoplimab targets transplant-associated thrombotic microangiopathy and has been studied for COVID-19 and acute respiratory distress syndrome. It is also developing OMS1029 for lectin pathway disorders and OMS527 for addiction and movement disorders, plus preclinical MASP-2 programs.
| Market Cap | $816.4M | Trading Days | 4222 |
| 52W High | 17.65 |
| 52W Low | 3.44 |
| % Off High | −36.09% |
| YTD | −34.34% | 1Y | 171.81% |
| 3Y | 158.72% | 5Y | −23.06% |
| 10Y | −3.59% | Since incept. (ann.) | 1.54% |
| Ann. Volatility (1Y) | 190.19% | Ann. Volatility (3Y) | 143.16% |
| Sharpe (1Y) | 1.13 | Sharpe (3Y) | 0.77 |
| Max Drawdown (1Y) | −49.53% | Max Drawdown (3Y) | −75.56% |
| Beta (3Y, vs SPY) | 4.41 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| ANNX | Annexon, Inc. | $770.9M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| MNPR | Monopar Therapeutics | $730.8M | — |
| JANX | Janux Therapeutics, Inc. | $914.8M | — |
